Switching from Neutral Protamine Hagedorn (NPH) Insulin to Insulin Glargine 300 U/mL in Older and Younger Patients with Type 2 Diabetes: A Post Hoc Analysis of a Multicenter, Prospective, Observational Study

B. Wolnik · A. Hryniewiecki · D. Pisarczyk-Wiza · T. Szczepanik · T. Klupa

Received: October 20, 2021 / Accepted: December 23, 2021 © The Author(s) 2022, corrected publication 2022

ABSTRACT

Introduction: Older age and longer disease duration are key risk factors for hypoglycemia in patients with type 2 diabetes (T2D) who receive insulin. Previous studies have shown that insulin glargine 300 U/mL (Gla-300) improves glycemic control and reduces the risk of hypoglycemia, but whether this effect is observed in older patients switching from neutral protamine Hagedorn (NPH) insulin is unclear.

Methods: In this multicenter, observational study involving patients with T2D aged ≥ 18 years with glycated hemoglobin (HbA1c) ≥ 8%, we compared the safety and effectiveness of switching from NPH insulin to Gla-300 in subgroups of patients differing by age (< 65 vs. ≥ 65 years) and duration of diabetes (≤ 13 vs. > 13 years).

Results: A total of 469 participants were included in the study. From baseline to 6 months after switching to Gla-300, mean HbA1c decreased from 9.23% to 8.13% (p < 0.001) among patients aged < 65 years (224 patients), and from 9.15% to 8.20% (p < 0.001) among those aged ≥ 65 years (245 patients). The proportion of patients with ≥ 1 episodes of hypoglycemia decreased from 19.1% to 13.6% (p = 0.11) among those aged < 65 years, and from 27.6% to 13.0% (p < 0.001) among those aged ≥ 65 years; the reduction was significantly greater in those aged ≥ 65 years (p < 0.001). The reduction in HbA1c was greater in those with a disease duration ≤ 13 years (p = 0.007), but the reduction in hypoglycemia was greater in those with a disease duration > 13 years (p < 0.0003).

Conclusion: The switch from NPH insulin to Gla-300 improved glycemic control in older patients with T2D and in those with a longer disease duration. Older patients with T2D and those with a longer disease duration benefited even more from the switch to Gla-300 than younger patients and those with a shorter...
disease duration, with significantly greater reductions in the risk of hypoglycemia.

**Keywords:** Type 2 diabetes; Elderly; Hypoglycemia; Insulin; NPH; Glargine 300

---

**Key Summary Points**

**Why carry out this study?**

Accumulating evidence shows that insulin glargine 300 U/mL (Gla-300) helps improve glycemic control in patients who do not achieve treatment targets on other insulin formulations and that the use of Gla-300 is also associated with reduced hypoglycemia risk. However, little is known about whether older patients with type 2 diabetes (T2D) and those with longer disease duration also gain benefits from Gla-300 treatment.

In this multicenter, observational study among 469 patients with T2D with glycated hemoglobin (HbA1c) C8%, we compared the safety and effectiveness of switching from neutral protamine Hagedorn (NPH) insulin to Gla-300 in subgroups of patients differing by age (< 65, ≥ 65 years) and duration of diabetes (< 13 vs. ≥ 13 years).

**What was learned from this study?**

From baseline to 6 months after switching to Gla-300, the mean reductions in HbA1c were similar in both age groups (approx. −1%), but the reduction in hypoglycemia frequency was much greater in patients aged > 65 years (approx. −14% of patients) than in those aged ≤ 65 years (approx. −6%). The reduction in HbA1c was greater in those with a disease duration ≤ 13 years (−1.16 vs. −0.87%), but the reduction in hypoglycemia was greater in those with a disease duration > 13 years (approx. −14% of patients vs. approx. −4%).

Older patients with T2D and those with a longer disease duration benefited even more from the switch to Gla-300 than younger patients and those with a shorter disease duration.

---

**DIGITAL FEATURES**

This article is published with digital features, including an infographic, to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.19539268.

**INTRODUCTION**

Strict glycemic control in type 2 diabetes (T2D) is key to preventing long-term complications but is associated with a substantially increased risk of hypoglycemia [1, 2]. Hypoglycemia can be life-threatening by itself or lead to life-threatening events, such as road traffic accidents, falls, or cardiac arrhythmias. Moreover, fear of hypoglycemia decreases quality of life [3].

Insulin therapy for patients with T2D is associated with a substantially higher risk of hypoglycemia compared with other treatments [4–6]. Older age is a key risk factor for hypoglycemia in patients with T2D who receive insulin, possibly due to cognitive impairment and atypical neurologic symptoms of hypoglycemia in these patients [7, 8]. Polypharmacy, chronic renal or hepatic impairment, and food insufficiency may also increase the risk of hypoglycemia in older patients with T2D [9]. In these patients, hypoglycemia is associated with multidimensional impairment, including a worsening of cognitive function [10, 11].

Reducing the risk of hypoglycemia is crucial in the management of elderly patients with T2D [12, 13] and can be achieved by choosing an adequate insulin formulation. For example, a patient-level meta-analysis of studies among patients aged ≥ 65 years showed that the risk of nocturnal hypoglycemia was lower with insulin glargine 300 U/mL (Gla-300) than with insulin glargine 100 U/mL (Gla-100) [14]. In a large, prospective,
observational study, we previously showed that switching from neutral protamine Hagedorn (NPH) insulin to Gla-300 significantly improved glycated hemoglobin (HbA1c) and decreased the risk of hypoglycemia [15]. In this post hoc analysis of data from this earlier study, we investigated whether the effectiveness and safety of switching from NPH insulin to Gla-300 differed between patients aged ≥ 65 years and those aged < 65 years. Also, because a long duration of diabetes is a well-recognized risk factor for hypoglycemia [4–7, 16], we additionally compared these outcomes by disease duration (≥ 13 or < 13 years).

METHODS

Study Setting

This observational study was conducted in accordance with the principles laid down in the 1964 Declaration of Helsinki by the 18th World Medical Assembly and its later amendments. The study was approved by the ethics committee of the Jagiellonian University, Krakow, Poland (decision no. 1072.61201.3.2017). All patients provided written informed consent before enrolment.

Participants

Eligible patients had T2D, were aged ≥ 18 years, had switched from NPH insulin to Gla-300, and had HbA1c ≥ 8% within 4 weeks prior to enrolment. Previous treatment with NPH insulin should have lasted for ≥ 6 months. The following NPH insulin regimens were allowed: basal insulin + oral antidiabetic drugs, basal-bolus insulin (bolus with either regular human insulin or analogs), or human regular premixed insulin containing NPH as the basal component. Detailed inclusion and exclusion criteria have been published previously [15]. Insulin titration was not standardized and was fully at the discretion of the attending physician.

Outcomes

This post-hoc analysis compared the safety and effectiveness of switching from NPH insulin to Gla-300 in subgroups of patients differing by age (< 65 vs. ≥ 65 years) and disease duration (< 13 vs. ≥ 13 years). The key effectiveness outcome was the value of HbA1c, and the key safety outcome was the proportion of patients with ≥ 1 episodes of hypoglycemia in the 4 weeks preceding baseline and in the 6 months after the switch to Gla-300. The remaining endpoints have been published in a previous report [15].

Statistical Analysis

Descriptive statistics were used in accordance with data distribution. Paired t-tests were used to compare HbA1c concentrations between patient subgroups differing by age (< 65 vs. ≥ 65 years; median age in our sample) or disease duration (< 13 vs. > 13 years; median disease duration in our sample). Unpaired t-tests were used to compare the change in HbA1c from baseline to 6 months after the switch to Gla-300 between patient subgroups. Paired t-tests were used to test the change in HbA1c after the switch within patient subgroups. The McNemar’s test was used to compare the change in the proportion of patients with ≥ 1 episode of hypoglycemia and the proportion with nocturnal hypoglycemia from baseline to 6 months after the switch to Gla-300 within patient subgroups. A comparison of percentages was used to assess differences between subgroups (Chi-squared statistic). A p value < 0.05 was considered to statistically significant. Statistica software (TIBCO Software Inc., Palo Alto, CA, USA) was used for all calculations.

RESULTS

Of the 499 patients enrolled in the study, 30 patients were not included in the analysis due to discontinued participation due to an unknown cause (n = 19), lost to follow-up (n = 7), switched to another insulin formulation (n = 2), discontinued treatment due to inefficacy (n =
Therefore, 469 participants with 6 months of follow-up were ultimately included in the analysis, of whom 224 were aged ≤ 65 years and 245 were aged > 65 years. The baseline characteristics of the 469 participants included in the analysis are shown in Table 1 according to age group. Of these 469 participants, 217 had a disease duration ≤ 13 years and 252 had a disease duration > 13 years. Details on the characteristics of the cohort have been published previously [15].

From baseline to 6 months after the switch to Gla-300, mean (standard deviation [SD]) HbA1c decreased from 9.23% (1.14) to 8.13% (1.20; p < 0.0001) among patients aged 1), and death (n = 1).
65 years, and from 9.15% (1.08) to 8.20%
(1.15; \( p < 0.001 \)) among those aged \( \geq 65 \) years.
The mean (SD) change in HbA1c did not differ significantly between age groups (\(-1.08\%
[1.19] \) vs. \(-0.94\% [1.15]; \( p = 0.186 \); Fig. 1a).

From baseline to 6 months after the switch
to Gla-300, the proportion of patients with \( \geq 1 \)
episodes of hypoglycemia decreased from 19.1% 
(\( n = 42 \)) to 13.6% (\( n = 30 \); a decrease of \(-5.5\% \);
\( p = 0.11 \)) among those aged \( \leq 65 \) years, and from 27.6% (\( n = 66 \)) to 13.0% (\( n = 31 \), decrease
of \(-14.6\%; \( p < 0.0001 \)) among those aged \( > 65 \) years (Fig. 2a). The change in the proportion
of patients \( \geq 1 \) episode of hypoglycemia was
significantly greater among those aged \( \geq 65 \) years (\( p = 0.001 \)). Among patients \( > 65 \) years and
\( \leq 65 \) years, the proportion of patients with nocturnal symptomatic hypoglycemia also
decreased significantly (\( p < 0.001 \)).

From baseline to 6 months after the switch
to Gla-300, mean (SD) HbA1c decreased from
9.20% (1.12) to 8.04% (1.22) among patients with a disease duration of \( \leq 13 \) years, and from
9.18% (1.10) to 8.28% (1.11) among those with a disease duration \( > 13 \) years. The mean (SD)
change in HbA1c was significantly greater in patients with a disease duration \( \leq 13 \) years than
in those with a longer disease duration
(\(-1.16\% [1.21] \) vs. \(-0.87\% [1.00]; \( p = 0.007 \); Fig. 1b).

From baseline to 6 months after the switch
to Gla-300, the proportion of patients with \( \geq 1 \)
episodes of hypoglycemia decreased from 17.1% 
(\( n = 37 \)) to 12.7% (\( n = 27 \); \(-4.4\%, \( p = 0.194 \))
among those with a disease duration \( \leq 13 \) years, and from 28.2% (\( n = 71 \)) to 13.8% (\( n = 34, \)
\(-14.4\%, \( p < 0.0001 \)) among those with a disease
duration \( > 13 \) years. The change in the

**DISCUSSION**

In this post hoc analysis of a prospective,
observational study among patients with poorly
controlled T2D who switched from NPH insulin
to Gla-300, the effectiveness of Gla-300 was
similar in those aged \( \leq 65 \) years and those aged
\( > 65 \) years, with comparable reductions in
HbA1c after 6 months of treatment. However,
HbA1c reductions were lower in those with a
disease duration \( > 13 \) years than in those with a
shorter disease duration. In all subgroups, the
improvement in glycemic control was accompanied
by a reduced frequency of hypoglycemia. However, the reduction in the
frequency of hypoglycemia was substantially
greater among older patients (\( \geq 65 \) years) and
those with a longer disease duration (\( > 13 \) years), such that the subgroup differences in
the frequency of hypoglycemia observed at baseline (higher frequency in older patients and those with a longer disease duration) had almost disappeared 6 months after switching to Gla-300.

Before the switch to Gla-300, the mean daily
total insulin dose was approximately 60 IU
(NPH insulin, approx. 40 IU, data published in original report [15]). During the study, the total daily insulin dose increased to approximately 70 IU (Gla-300, approx. 30 IU) [15]. Thus, the total dose of insulin increased, but the dose of basal insulin decreased, which might partly explain the simultaneous reductions in HbA1c and hypoglycemia frequency in our sample. Additionally, the decrease in the risk of hypoglycemia in our study might be associated with a reduction in the use of sulfonylureas (approx. 13% of patients at baseline; approx. 9% at the end-of-study), as the use of other antidiabetic medications did not change substantially [15]. The reductions in HbA1c and the risk of hypoglycemia in both age groups could also be due to the trial effect, as patients were likely to be monitored more frequently and had easier access to a diabetes specialist compared with usual care. As there was no placebo arm in our study, we cannot estimate the size of this effect. Despite an increase in the total daily insulin dose during the study, the mean body weight did not change considerably (an increase of < 0.5 kg) [15].

Older patients with T2D who use insulin are at substantial risk of hypoglycemia, which can be life-threatening. A study using blinded continuous glucose monitoring among patients with poorly controlled T2D (HbA1c > 8%) aged ≥ 69 years showed that, within 3 days, 65% experienced ≥ 1 episodes of hypoglycemia (blood glucose < 70 mg/dL), with > 90% of episodes undetected by symptoms or routine self-monitoring of blood glucose [17]. In our study, before switching to Gla-300, the proportion of patients with ≥ 1 episodes of hypoglycemia was much greater among those aged > 65 years than among those aged ≤ 65 years (approx. 27% vs. approx. 19%). The causes of increased risk of hypoglycemia in older patients include atypical symptoms of hypoglycemia, cognitive impairment, and food insufficiency; overtreatment is also an important factor [18]. To reduce the frequency of hypoglycemia, the recommended glycemic targets in older patients with T2D are less strict (HbA1c < 7.5%), particularly in those with serious comorbidities, including cognitive impairment (HbA1c < 8.0–8.5%) [13]. Moreover, deintensification algorithms, which propose a reduction in insulin dose, have been developed specifically for older patients with T2D to help reduce the risk of hypoglycemia [19].

However, switching to a new-generation basal insulin analog can reduce the frequency of hypoglycemia without compromising, or even necessarily improving, glycemic control. Moreover, accumulating evidence shows that insulin analogs can be used safely in older patients with T2D. In a real-world study of approximately 2000 patients with T2D aged ≥ 65 years, switching from basal insulin to Gla-100/insulin detemir or Gla-300 reduced both HbA1c and the frequency of hypoglycemia [20]. The REALI European Pooled Data Analysis among patients with T2D showed that treatment with Gla-300 improved glycemic control similarly across age groups (< 50 years to > 80 years), and the overall frequency of hypoglycemia was low (approx. 10% of patients with ≥ 1 episodes across all age groups) [21].
insulin-naïve patients with T2D who started
either insulin degludec 100 U/mL or Gla-300,
improvements in HbA1c and the incidence of
hypoglycemia were similar in patients aged < 65 years and those aged > 65 years for both
insulin formulations (approx. 70% with ≥ 1
episodes of hypoglycemia) [22]. The LIGHT-
NING study compared the incidence of hypo-
glycemia in nearly 200,000 patients with T2D
on Gla-300, or first-generation (Gla-100, insulin
detemir) or second-generation (insulin deglu-
dec) basal-insulin analogs. Rates of severe
hypoglycemia among insulin-naïve patients
aged ≥ 65 years were lower with Gla-300 than
with the other insulin formulations (although
differences were only significant vs. insulin
detemir and Gla-100) [23]. A patient-level meta-
analysis of the EDITION 1, 2, and 3 trials com-
paring Gla-100 and Gla-300 showed that the
benefits of these analogs were similar between
patients aged ≥ 65 years and those aged < 65 years, but the risk of nocturnal hypo-
glycemia was lower with Gla-300 [14]. By
showing that Gla-300 improved glycemic con-
trol and reduced the frequency of hypoglycemia
both in patients aged 65 years and in those aged
> 65 years, our study adds to the existing evi-
dence supporting the use of Gla-300 in older
patients with poorly controlled T2D, particu-
larly because the reduction in the frequency of
hypoglycemia in our study was greater among
patients aged > 65 years.

The risk of hypoglycemia in patients with
T2D uncontrolled on different insulin regimens
decreased substantially after switching to Gla-
300 in previous real-world studies [24, 25]. In
our study, the reduction in hypoglycemia risk
was greater in patients aged > 65 years primarily
because these patients had substantially greater
hypoglycemia frequency at baseline. In prin-
ciple, hypoglycemia results from inadequate
insulin treatment, with older patients having
less effective counterregulatory mechanisms.
Therefore, although optimizing insulin treat-
ment helps avoid hypoglycemia in all patients,
the benefits might be the greatest among those
with less effective counterregulatory mechani-
isms, including older patients.

In addition to old age, long disease duration
is an important risk factor for hypoglycemia
among patients with T2D, which is due—
among others things—to an impaired counter-
regulatory response to hypoglycemia [5, 26]. We
found that the switch from NPH insulin to Gla-
300 reduced the frequency of hypoglycemia in
patients with long-lasting diabetes, although
these patients had a lower reduction in HbA1c
than did those with a shorter disease duration.
A meta-analysis of four studies comparing
insulin glargine and NPH insulin among
patients with T2D showed that the risk of noc-
turnal hypoglycemia correlated positively with
disease duration among those receiving NPH
but not among those receiving insulin glargine
[27]. Patients with a long disease duration
therefore seem to benefit particularly from Gla-
300 (vs. NPH insulin).

**CONCLUSIONS**

The results of our study indicate that patients
aged > 65 years benefit even more from
switching from NPH insulin to Gla-300 than do
those aged ≤ 65 years, with a similar reduction
in HbA1c but a greater reduction in the fre-
quency of hypoglycemia. Similarly, the reduc-
tion in the frequency of hypoglycemia was
higher in patients with a longer duration of T2D
(≥ 13 years), but the reduction in HbA1c was
smaller than in those with a shorter disease
duration.

**ACKNOWLEDGEMENTS**

**Funding.** This study was funded by Sanofi.
The medical writing and language assistance
were sponsored by Sanofi-Aventis and provided
by Rafal Szot from Proper Medical Writing Sp. z
o.o., Warsaw, Poland. The Rapid Service Fee was
paid by Sanofi.

**Authorship.** All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
article, take responsibility for the integrity of
the work as a whole, and have given their
approval for this version to be published. All
authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.

**Authorship Contributions.** B Wolnik, A Hryniewiecki, D Wiza, T Szczepanik, and T Klupa: concept design, data analysis and interpretation, drafting publication, critical revision, and final approval.

**List of Investigators.** Moroz Ewa, Seidel Wojciech, Szydłowska Ewa, Galicka-Stankowska Dorota, Ruxer Jan, Łęski Tomasz, Sumper Rafał, Zwiącz-Zawada Alicja, Krawczyk Małgorzata, Bień Małgorzata, Dolecka-Słusarczyk Magdalena, Morkis-Siedlecka Maria, Szczepanik Tomasz, Kozanecki Sławomir, Frączek Dorota, Kurzepa Wiesława, Laszewska Grażyna, Sawerszewczyk Joanna, Śliwońska Teresa, Wasilewska Katarzyna, Jastrzębska-Pasierb Mirosława, Madejska-Szymańska Ewa, Bodys Artur, Tomczykowska Małgorzata, Zwolak Agnieszka, Modzelew ska Anna, Wdowiak-Barton Barbara, Błońska-Zyber Małgorzata, Grzyb Beata, Grzywacz Janina, Herczek-Pazdziora Jadwiga, Lebek-Ordon Anna, Petrulewicz-Salamon Iwona, Pyrzak Barbara, Soróbka Barbara, Stasińska Teresa, Szykowna Irena, Żykiewicz-Jaruga Danuta, Towpik Ivona, Piarczyk-Wiza Dorota, Paciorkowski Andrzej, Gawre cki Andrzej, Studarska Ewa, Połońska-Lemańska Małgorzata, Sienkiewicz Adam, Ślężak Aleksandra, Pynka Sławomir, Kwiecińska Ewa, Polaszewska-Muszyńska Mirosława, Fabisiak Jacek, Żadan Martina.

**Disclosures.** B Wolnik, D Wiza, T Szczepanik, A Hryniewiecki, and T Klupa have received remunerations/fees for activities on behalf of Sanofi-Aventis, Eli Lilly, Novo Nordisk, Bioton, Polfa Tarchomin, Servier, Astra-Zeneca, Boehringer-Ingelheim, Medtronic, Roche, and Abbott. A. Hryniewiecki was a Sanofi-Aventis employee at the time when the study was conducted.

The sponsor played no role in assigning treatments, making dose decisions, or identifying patients during the study.

**Compliance with Ethics Guidelines.** This observational study was conducted in accordance with the principles laid down in the 1964 Declaration of Helsinki by the 18th World Medical Assembly and its later amendments. The study was approved by the ethics committee of the Jagiellonian University, Krakow, Poland (decision no. 1072.61201.3.2017). All patients provided written informed consent before enrolment.

**Data Availability.** The data supporting conclusions of the study can be accessed on request. To request for data, the readers should contact the corresponding author (T Klupa) directly. Qualified researchers may request access to patient-level data and related documents (including, for example, the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications). Patient-level data will be anonymized, and study documents will be redacted to protect the privacy of the trial participants. Further details on Sanofi’s data-sharing criteria, eligible studies, and process for requesting access can be found at https://www.clinicalstudydatarequest.com.

**Open Access.** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
REFERENCES

1. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53. https://doi.org/10.1016/S0140-6736(98)07019-6.

2. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343:d6898. https://doi.org/10.1136/bmj.d6898.

3. Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ. 2011;14:646–55. https://doi.org/10.3111/13696998.2011.610852.

4. UK Prospective Diabetes Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140–7. https://doi.org/10.1007/s00125-007-0599-y.

5. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 2005;28:2948–61. https://doi.org/10.2337/diacare.28.12.2948.

6. van Meijel LA, de Vegt F, Abbink EJ, et al. High prevalence of impaired awareness of hypoglycemia and severe hypoglycemia among people with insulin-treated type 2 diabetes: the Dutch Diabetes Pearl Cohort. BMJ Open Diabetes Res Care. 2020;8:e000935. https://doi.org/10.1136/bmjdrcc-2019-000935.

7. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med. 2003;20:1016–21. https://doi.org/10.1046/j.1464-5491.2003.01072.x.

8. Jaap AJ, Jones GC, McCrimmon RJ, Deary IJ, Frier BM. Perceived symptoms of hypoglycaemia in elderly type 2 diabetic patients treated with insulin. Diabet Med. 1998;15:398–401. https://doi.org/10.1002/(SICI)1096-9136(199805)15:5<398::AID-DIA595>3.0.CO;2-B.

9. Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus. Drugs Aging. 2004;21:511–30. https://doi.org/10.2165/00022512-200421080-00003.

10. Pilotto A, Noale M, Maggi S, et al. Hypoglycemia is independently associated with multidimensional impairment in elderly diabetic patients. Biomed Res Int. 2014;2014:1–7. https://doi.org/10.1155/2014/906103.

11. Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care. 2011;34:1329–36. https://doi.org/10.2337/dc10-2377.

12. Rosenzweig JL, Conlin PR, Goncalvo JD, et al. Endocrine society measures set for older adults with type 2 diabetes who are at risk for hypoglycemia. J Clin Endocrinol Metab. 2019;105(2020):969–90. https://doi.org/10.1210/clinem/dgzz250.

13. American Diabetes Association. 12. Older adults: standards of medical care in diabetes—2019. Diabetes Care. 2019;42:S139–47. https://doi.org/10.2337/dc19-S012.

14. Yale J-F, Aroda VR, Charbonnel B, et al. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: a patient-level meta-analysis examining older and younger adults with type 2 diabetes. Diabetes Metab. 2020;46:110–8. https://doi.org/10.1016/j.diabet.2018.10.002.

15. Wolnik B, Wiza D, Szczepanik T, Syta A, Klupa T. Switching from neutral protamine hagedorn insulin to insulin glargine 300 U/mL improves glycaemic control and reduces hypoglycaemia risk: results of a multicentre, prospective, observational study. J Diabetes Res. 2020;2020:1–8. https://doi.org/10.1155/2020/8751348.

16. Akram K, Pedersen-Bjergaard U, Carstensen B, Borch-Johnsen K, Thorsteinsson B. Frequency and risk factors of severe hypoglycaemia in insulin-treated type 2 diabetes: a cross-sectional survey. Diabet Med. 2006;23:750–6. https://doi.org/10.1111/j.1464-5491.2006.01880.x.

17. Munshi MN, Segal AR, Suhl E, et al. Frequent hypoglycemia among elderly patients with poor glycemic control. Arch Intern Med. 2011;171:362–4. https://doi.org/10.1001/archinternmed.2010.539.

18. Alagiakrishnan K, Mereu L. Approach to managing hypoglycemia in elderly patients with diabetes. Postgrad Med. 2010;122:129–37. https://doi.org/10.3810/pgm.2010.05.2150.

19. Munshi MN, Slyne C, Segal AR, Saul N, Lyons C, Weiniger K. Simplification of insulin regimen in older adults and risk of hypoglycemia. JAMA Intern Med. 2016;176:1023. https://doi.org/10.1001/jamainternmed.2016.2288.
20. Bailey TS, Wu J, Zhou FL, et al. Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3). Diabetes Obes Metab. 2019;21:2384–93. https://doi.org/10.1111/dom.13818.

21. Bonadonna RC, Mauricio D, Müller-Wieland D, et al. Impact of age on the effectiveness and safety of insulin glargine 300 U/mL: results from the REALI European pooled data analysis. Diabetes Ther. 2021;12:1073–97. https://doi.org/10.1007/s13300-021-01030-0.

22. Bolli GB, Cheng A, Charbonnel B, et al. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial. Diabetes Obes Metab. 2021;23(7):1588–93. https://doi.org/10.1111/dom.14372.

23. Pettus J, Roussel R, Liz Zhou F, et al. Rates of hypoglycemia predicted in patients with type 2 diabetes on insulin glargine 300 U/mL versus first- and second-generation basal insulin analogs: the real-world LIGHTNING study. Diabetes Ther. 2019;10:617–33. https://doi.org/10.1007/s13300-019-0568-8.

24. Velojic-Golubovic M, Cric V, Dimitrijevic M, et al. Clinical benefit of insulin glargine 300 U/mL among patients with type 2 diabetes mellitus previously uncontrolled on basal or premixed insulin in Serbia: a prospective, observational, single-arm, multicenter, real-world study. Diabetes Ther. 2021;12:2049–58. https://doi.org/10.1007/s13300-021-01074-2.

25. Kamenov Z, Pehlivanova V, Kuneva T, et al. Real-world effectiveness and safety of insulin glargine 300 U/mL in patients with T2D uncontrolled on NPH or premixed insulins as part of routine clinical practice in Bulgaria: ToUPGRADE study. Diabetes Ther. 2021;12:913–30. https://doi.org/10.1007/s13300-021-01022-0.

26. Graveling AJ, Frier BM. Impaired awareness of hypoglycaemia: a review. Diabetes Metab. 2010;36:S64–74. https://doi.org/10.1016/S1262-3636(10)70470-5.

27. Dailey GE, Gao L, Aurand L, Garg SK. Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin. Diabetes Obes Metab. 2013;15:1085–92. https://doi.org/10.1111/dom.12131.